Insulin biosimilars are a new class of insulin products that are highly similar to already approved insulin products known as reference products. Biosimilars offer compelling opportunities to reduce healthcare costs and expand access to treatment for millions of people with diabetes worldwide. However, effective regulation is needed to ensure appropriate substitution and exchangeability.

Development and Approval Process for Biosimilars

Developing an Insulin Biosimilars requires extensive characterization, nonclinical and clinical evaluation to demonstrate similarity in molecular structure, biological activity, safety and efficacy compared to the reference product. Phase I pharmacokinetic/pharmacodynamic trials establish equivalence, with some Phase III confirmatory efficacy and safety trials.

Regulatory agencies like the FDA utilize a stepwise, "totality-of-the-evidence" approach. Data from analytical, nonclinical and clinical studies are reviewed collectively to establish biosimilarity and determine whether it can be expected to produce the same clinical result as the reference product in any given patient. While extrapolation of indications across product classes is not automatic, it may be approved based on the overall similarity assessment.

Potential Cost Savings from Biosimilars

Biosimilar competition can lead to substantial savings as companies aim to capture market share. Studies estimate US savings of $54 billion over 10 years from biosimilars in oncology, diabetes and other areas. For diabetes specifically, it's projected biosimilars could save $5.4 billion over 5 years in the US alone. Lower prices increase access to care where cost barriers exist.

Get more insights on – Insulin Biosimilars